Breaking: B.Riley FBR Reaffirms $25.0000 Price Target On Clementia Pharmaceuticals Inc (CMTA) Shares, Reaffirms Their Original “Buy” Rating

May 25, 2018 - By Migdalia James

Clementia Pharmaceuticals Inc (CMTA) Rating Reaffirmed

EU: In analysts report released on Wednesday, 23 May, B.Riley FBR reiterated their “Buy” rating on Clementia Pharmaceuticals Inc (CMTA) shares. They now have a $25.0000 target on the company. B.Riley FBR’s target would indicate a potential upside of 66.22 % from the company’s current stock price.

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) Ratings Coverage

Among 2 analysts covering Clementia Pharmaceuticals Inc (CMTA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Clementia Pharmaceuticals Inc has $2500 highest and $25 lowest target. $25’s average target is 66.22% above currents $15.04 stock price. Clementia Pharmaceuticals Inc had 2 analyst reports since March 27, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, March 27 by FBR Capital.

The stock increased 1.28% or $0.19 during the last trading session, reaching $15.04. About 161,303 shares traded or 229.63% up from the average. Clementia Pharmaceuticals Inc. (CMTA) has 0.00% since May 25, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts await Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) to report earnings on August, 9. After $-0.42 actual earnings per share reported by Clementia Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -14.29 % EPS growth.

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. The company has market cap of $477.03 million. The Company’s lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models. It currently has negative earnings. The firm is developing palovarotene for the treatment of fibrodysplasia ossificans progressiva and multiple osteochondroma, as well as has one Phase III and Phase II/III trials for two separate indications.

More notable recent Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) news were published by: Streetinsider.com which released: “Clementia Pharmaceuticals (CMTA) Highlights Positive Phase 2 Part B Data from Ongoing Phase 2 Clinical Trial …” on May 23, 2018, also Globenewswire.com with their article: “Clementia Reports First Quarter 2018 Operating Results and Pipeline Updates” published on May 09, 2018, Benzinga.com published: “33 Stocks Moving In Wednesday’s Mid-Day Session” on May 23, 2018. More interesting news about Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) were released by: Businesswire.com and their article: “Prevail Therapeutics Appoints Industry Leader Francois Nader, MD, to its Board of Directors” published on May 24, 2018 as well as Schaeffersresearch.com‘s news article titled: “Tiffany Stock Eyes Best Day in Years After Earnings, Share Buyback” with publication date: May 23, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: